Expert Interview
Discussing Incyte Corp's Phase 3 results of LBA-1 Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma, as discussed at the ASH Annual Meeting.
Ticker(s): INCYInstitution: Oncology Hematology Associates of West Broward
- Practicing hematology/oncology for the past 30 years and is currently the President at Oncology and Hematology Associates of West Broward
- Vice Chief of Staff at Northwest Medical Center and is a Staff Physician with privileges at University Hospital and Medical Center, Broward Health Coral Springs and Florida Medical Center.
How many patients do you manages for follicular lymphoma?
Added By: nikki_adminOn a scale from 1-10 (10 being extremely excited), how excited are you for the Phase 3 results of LBA-1 Tafasitamab?
Added By: nikki_adminHow does the data from InMind compare with the data from bispecifics like epcoritamab and mosunetuzumab from an efficacy and safety standpoint?
Added By: jnelson3892What are your treatment goals with R/R FL patients? Do you prefer fixed duration treatments or continuous? Which do you patients tend toprefer?
Added By: jnelson3892What other regimens being studied in R/RFL are you excited about? Which are you looking forward to seeing data on at ASH?
Added By: jnelson3892Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
